Arrowhead Pharmaceuticals, Inc.
ARWR
$15.93
$0.130.82%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,436.97% | -98.62% | -98.52% | -92.33% | -87.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,436.97% | -98.62% | -98.52% | -92.33% | -87.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1,436.97% | -98.62% | -98.52% | -92.33% | -87.00% |
| SG&A Expenses | 11.26% | 12.58% | 13.79% | 2.97% | -5.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.34% | 30.61% | 35.65% | 29.80% | 20.24% |
| Operating Income | 74.98% | -109.06% | -193.21% | -203.16% | -214.36% |
| Income Before Tax | 68.15% | -113.88% | -196.60% | -205.39% | -222.31% |
| Income Tax Expenses | 539.93% | 218.86% | -199.39% | -128.35% | -114.36% |
| Earnings from Continuing Operations | 67.61% | -114.48% | -191.34% | -197.15% | -213.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 59.26% | 62.98% | 155.00% | 182.00% | 250.89% |
| Net Income | 69.42% | -115.53% | -192.04% | -197.41% | -213.43% |
| EBIT | 74.98% | -109.06% | -193.21% | -203.16% | -214.36% |
| EBITDA | 78.72% | -112.51% | -202.58% | -213.09% | -226.81% |
| EPS Basic | 68.02% | -86.16% | -160.56% | -173.05% | -197.91% |
| Normalized Basic EPS | 69.43% | -86.20% | -166.00% | -181.06% | -205.74% |
| EPS Diluted | 67.22% | -85.99% | -160.32% | -172.72% | -197.07% |
| Normalized Diluted EPS | 68.88% | -85.80% | -165.16% | -180.05% | -204.43% |
| Average Basic Shares Outstanding | 13.90% | 15.94% | 12.24% | 8.56% | 4.83% |
| Average Diluted Shares Outstanding | 14.15% | 15.57% | 11.87% | 8.20% | 4.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |